CervoMed Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CRVO Nasdaq 2834 www.cervomed.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for CervoMed Inc.

Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates - May 7th, 2026 5:05 pm
IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates - May 5th, 2026 5:10 am
CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies - Apr 22nd, 2026 5:30 am
CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting - Apr 7th, 2026 5:30 am
CervoMed (CRVO)’s Q4 Results Feature Advancements in Its Neflamapimod Program for Dementia Lewy Bodies (DLB) - Mar 25th, 2026 1:28 pm
CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-Pathology - Mar 19th, 2026 5:30 am
CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates - Mar 17th, 2026 5:30 am
CervoMed Inc. (CRVO) Reports Q4 Loss, Lags Revenue Estimates - Mar 13th, 2026 4:15 pm
CervoMed Announces Presentations at Upcoming AD/PD™ 2026 Scientific Conference - Mar 12th, 2026 5:00 am
CervoMed to Participate in Upcoming Investor Conferences - Mar 5th, 2026 5:30 am
CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies - Mar 4th, 2026 5:30 am
Pharming Group Gears Up to Report Q4 Earnings: What's in the Cards? - Mar 3rd, 2026 6:07 am
CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis - Feb 18th, 2026 4:00 am
Pleasing Signs As A Number Of Insiders Buy CervoMed Stock - Dec 10th, 2025 4:41 am
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies - Dec 4th, 2025 3:00 pm
CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB) - Dec 2nd, 2025 5:00 am
CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference - Nov 24th, 2025 5:00 am
CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates - Nov 10th, 2025 5:00 am
CervoMed Inc. (CRVO) Reports Q3 Loss, Misses Revenue Estimates - Nov 7th, 2025 3:55 pm
Atara Biotherapeutics (ATRA) Surges 10.0%: Is This an Indication of Further Gains? - Nov 7th, 2025 4:45 am